EMA recommends approval of bevacizumab Lytenava

Biosimilars/News | Posted 22/05/2024 comments 0
Blue eye with data points

On 21 March 2024, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization ...

More >
An update on the joint EMA-HMA statement on interchangeability of biosimilar
Posted 12/05/2023

On 21 April 2023, the European Medicines Agency (EMA) and the Heads of Medicines Agenci...

Regulation V13H16
Inflation Reduction Act explained
Posted 24/07/2023

The US Assistant Secretary for Planning and Evaluation’s (ASPE) ‘Medicare Part B drugs:...

Switching V19A17
Canada’s Prince Edward Island adopts biosimilars switching policy
Posted 07/11/2023

Canada’s Prince Edward Island (PEI) becomes the 11th Canadian jurisdiction to...

Home/Non‐Biological Complex Drugs
Liposome V15L11

On 4 April 2018, the US Food and Drug Administration (FDA) issued a new draft guidance...

More >